🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. C1 esterase inhibitor [human] (C1INH-nf)

    Takeda

    Hereditary Angioedema

    phase 3 mab completed

    5 trials

  2. C1 esterase inhibitor [human] liquid

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  3. CINRYZE 500

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 mab completed

    1 trial

  4. CINRYZE 500 U

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  5. Cabozantinib

    Takeda

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  6. Candesartan

    Takeda

    Heart Failure

    phase 3 small molecule completed

    1 trial

  7. Candesartan Cilexetil

    Takeda

    Stroke

    phase 3 small molecule completed

    1 trial

  8. Candesartan and standard chronic heart disease therapy

    Takeda

    Heart Failure

    phase 3 small molecule terminated

    1 trial

  9. Cinryze®

    Takeda

    Acute Antibody-Mediated Rejection (AMR)

    phase 3 mab terminated

    1 trial

  10. Cohort 1: Lubiprostone Capsule, Fasted

    Takeda

    Healthy Volunteers

    phase 3 small molecule completed

    1 trial

  11. Cx601

    Takeda

    Crohn's Disease

    phase 3 other completed

    3 trials

  12. Cyclobenzaprine HCl

    Takeda

    Neck Pain

    phase 3 small molecule completed

    1 trial

  13. Cyproterone acetate

    Takeda

    Adenocarcinoma, Prostate

    phase 3 small molecule completed

    1 trial

  14. DX-2930

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    3 trials

  15. DX-2930 - 300mg/2wk

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  16. Darvadstrocel

    Takeda

    Complex Perianal Fistulas in Adult Participants With Crohn's Disease

    phase 3 mab completed

    1 trial

  17. Delayed and extended release mesalazine

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  18. Dexlansoprazole

    Takeda

    Erosive Esophagitis

    phase 3 small molecule terminated

    2 trials

  19. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    2 trials

  20. Dexlansoprazole

    Takeda

    Heartburn

    phase 3 small molecule completed

    1 trial

  21. Dexlansoprazole MR

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    4 trials

  22. Dexlansoprazole MR

    Takeda

    Esophagitis, Reflux

    phase 3 small molecule completed

    5 trials

  23. Dexlansoprazole MR QD

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    1 trial

  24. Doxorubicin

    Takeda

    Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  25. Doxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bleomycin 15000 IU Powder for solution for injection/infusion, Detimedac 200 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung, Doxorubicin hydrochloride 2 mg/ml solution for infusion, ADCETRIS 50 mg powder for concentrate for solution for infusion, Vinblastine Sulfate 1 mg/ml solution for injection, Dacarbazine medac 200 mg, powder for solution for injection/infusion, Vinblastinsulfat Teva® 1 mg/ml Injektions

    Takeda

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  26. Dynepo (Epoetin delta)

    Takeda

    Anemia

    phase 3 small molecule terminated

    1 trial

  27. ERYTHROPOIETIN , Elritercept

    Takeda

    Myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  28. Elritercept

    Takeda

    Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  29. Emicizumab

    Takeda

    Hemophilia A

    phase 3 small molecule active

    1 trial

  30. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 108 mg solution for injection in pre-filled pen

    Takeda

    Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial

  31. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Active Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial

  32. Epoetin

    Takeda

    Chronic Kidney Disease

    phase 3 small molecule completed

    1 trial

  33. Escitalopram

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  34. Expanded autologous adipose-derived adult stem cells (eASCs)

    Takeda

    Complex Perianal Fistula

    phase 3 small molecule terminated

    1 trial

  35. Extended-release Guanfacine HCl (Intuniv, SPD503)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  36. Extended-release Guanfacine Hydrochloride

    Takeda

    Attention-deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    3 trials

  37. FEIBA

    Takeda

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  38. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda

    Acute Fungal Otitis Externa

    phase 3 small molecule terminated

    1 trial

  39. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda

    Acute Otitis Externa

    phase 3 small molecule terminated

    1 trial

  40. FST201 (dexamethasone 0.1% with povidone-iodine 1%)

    Takeda

    Acute Otitis Externa

    phase 3 small molecule completed

    1 trial

  41. Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)

    Takeda

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  42. Fasiglifam (TAK-875)

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

  43. Fasiglifam (TAK-875)

    Takeda

    Glycemic Control

    phase 3 small molecule terminated

    1 trial

  44. Fazirsiran Injection

    Takeda

    Alpha1-Antitrypsin Deficiency

    phase 3 small molecule active

    3 trials

  45. Febuxostat

    Takeda

    Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  46. Febuxostat IR

    Takeda

    Gout

    phase 3 small molecule completed

    2 trials

  47. Fibrinogen (human) + thrombin (human) (TachoSil)

    Takeda

    Surgical Resection of Superficial Renal Tumour

    phase 3 other completed

    1 trial

  48. Flomoxef

    Takeda

    Urinary Tract Infection

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.